The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Natalia Davis - Intern Health - Analyst
: Hi. Thank you so much for taking my questions. Just a couple from me. The first is, could we get a sense of the growth rate that you've seen for the
Fior & Gentz business and if it's in line with preacquisition double digit growth. And the second question, could you just provide some insights into
how your R&D and SG&A costs are projected to evolve through 2025 and 2026? Particularly in light of any planned product launches or the rollout
of NAVI and Icon MPK? Thank you.
Question: Natalia Davis - Intern Health - Analyst
: Thank you so much.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 22, 2024 / 7:00AM, EMBLA.CO - Q3 2024 Embla Medical hf Earnings Call
Question: Yiwei Zhou - SEB - Analyst
: Hi, good morning. Thank you for taking my question. I have a few questions. I do one at a time. Firstly, just looking at your US business and especially
the pricing support segment, I remember the first half you were impacted by the cyber-attack on your media customer. And I understand that this
has somehow eased here. But what can explain the weakness here in Q3? And what is your expectation for the remaining of the year?
Question: Yiwei Zhou - SEB - Analyst
: And thanks and just want to follow up here. Is there any market you are looking into a possibility to divest the pricing support business or any
market has been sort of a long term loss making. And as you could see that could lift your group margin as you did in the France during the COVID
times.
Question: Yiwei Zhou - SEB - Analyst
: Okay. And when you mentioned the price pressure, could you elaborate a bit if or confirm if that is sort of increasing competition due to the
increasing competition?
Question: Yiwei Zhou - SEB - Analyst
: Great. Thank you. And the next question is on the Australia. I'll send you have benefits a bit from the pent up demand from this delay reimbursement
approval. Could you please indicate that on the Q3 growth and maybe also comment on the Q4 if you can give any indication?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 22, 2024 / 7:00AM, EMBLA.CO - Q3 2024 Embla Medical hf Earnings Call
Question: Yiwei Zhou - SEB - Analyst
: Okay. And so it is a very small posture boost on your growth, here in the quarter?
Question: Yiwei Zhou - SEB - Analyst
: Okay, great, thanks. And my next question on the gross margin here in Q3, improved year-over-year, but actually lower than Q2. And it is there like
seasonality here. And if you could also confirm that you have not been impacted by a higher shipping cost?
Question: Yiwei Zhou - SEB - Analyst
: Perfect. Thanks. Last question on the -- your CapEx to sales guidance. And could you remind us of what is driven the higher investment here?
Question: Yiwei Zhou - SEB - Analyst
: Okay. Is it the capacity or automation? Because we also understand on the other hand, you have been cutting costs also in the production.
Question: Yiwei Zhou - SEB - Analyst
: Okay, great. Thanks. All right, jump back to the queue.
| 
